Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs

References

• KellyERussellSJHistory of oncolytic viruses: genesis to genetic engineeringMol Ther200715465165917299401
   PubMed Web of Science ®Google Scholar
• MartuzaRLMalickAMarkertJMRuffnerKLCoenDMExperimental therapy of human glioma by means of a genetically engineered virus mutantScience199125250078548561851332
   PubMed Web of Science ®Google Scholar
• Campadelli-FiumeGDe GiovanniCGattaVNanniPLolliniPLMenottiLRethinking herpes simplex virus: the way to oncolytic agentsRev Med Virol201121421322621626603
   PubMed Web of Science ®Google Scholar
• MinetaTRabkinSDMartuzaRLTreatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutantCancer Res19945415396339668033122
   PubMed Web of Science ®Google Scholar
• CassadyKAParkerJNHerpesvirus vectors for therapy of brain tumorsOpen Virol J2010410310820811578
   PubMedGoogle Scholar
• ManservigiRArgnaniRMarconiPHSV Recombinant Vectors for Gene TherapyOpen Virol J2010412315620835362
   PubMedGoogle Scholar
• VargheseSRabkinSDOncolytic herpes simplex virus vectors for cancer virotherapyCancer Gene Ther200291296797812522436
   PubMed Web of Science ®Google Scholar
• TodaMMartuzaRLKojimaHRabkinSDIn situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activityJ Immunol19981609445744649574551
   PubMed Web of Science ®Google Scholar
• VargheseSRabkinSDLiuRNielsenPGIpeTMartuzaRLEnhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancersCancer Gene Ther200613325326516179929
   PubMed Web of Science ®Google Scholar
• ParkerJNMelethSHughesKBGillespieGYWhitleyRJMarkertJMEnhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12Cancer Gene Ther200512435936815678154
   PubMed Web of Science ®Google Scholar
• CarewJFKoobyDAHaltermanMWKimSHFederoffHJFongYA novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genesMol Ther20014325025611545616
   PubMed Web of Science ®Google Scholar
• TodoTMartuzaRLDallmanMJRabkinSDIn situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunityCancer Res200161115316111196154
   PubMed Web of Science ®Google Scholar
• HuJCCoffinRSDavisCJA phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factorClin Cancer Res200612226737674717121894
   PubMed Web of Science ®Google Scholar
• MalhotraSKimTZagerJUse of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomasSurgery2007141452052917383529
   PubMed Web of Science ®Google Scholar
• KaufmanHLBinesSDOPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanomaFuture Oncol20106694194920528232
   PubMed Web of Science ®Google Scholar
• KaufmanHLKimDWDeRaffeleGMitchamJCoffinRSKim-SchulzeSLocal and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanomaAnn Surg Oncol201017371873019915919
   PubMed Web of Science ®Google Scholar
• NakamuraHMullenJTChandrasekharSPawlikTMYoonSSTanabeKKMultimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracilCancer Res200161145447545211454690
   PubMed Web of Science ®Google Scholar
• ChaseMChungRYChioccaEAAn oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapyNat Biotechnol19981654444489592392
   PubMed Web of Science ®Google Scholar
• BraidwoodLDunnPDHardySEvansTRBrownSMAntitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapyAnticancer Res20092962159216619528476
   PubMed Web of Science ®Google Scholar
• SheridanCAmgen announces oncolytic virus shrinks tumorsNat Biotechnol201331647147223752412
   PubMed Web of Science ®Google Scholar
• FisherRPusztaiLSwantonCCancer heterogeneity: implications for targeted therapeuticsBr J Cancer2013108347948523299535
   PubMed Web of Science ®Google Scholar
• PaludanSRBowieAGHoranKAFitzgeraldKARecognition of herpesviruses by the innate immune systemNat Rev Immunol201111214315421267015
   PubMed Web of Science ®Google Scholar
• LilleyCEChaurushiyaMSBoutellCEverettRDWeitzmanMDThe intrinsic antiviral defense to incoming HSV-1 genomes includes specific DNA repair proteins and is counteracted by the viral protein ICP0PLoS Pathog201176e100208421698222
   PubMed Web of Science ®Google Scholar
• ZachosGKoffaMPrestonCMClementsJBConnerJHerpes simplex virus type 1 blocks the apoptotic host cell defense mechanisms that target Bcl-2 and manipulates activation of p38 mitogen-activated protein kinase to improve viral replicationJ Virol20017562710272811222695
   PubMed Web of Science ®Google Scholar
• HeoJReidTRuoLRandomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNat Med201319332933623396206
   PubMed Web of Science ®Google Scholar
• ChouTCTalalayPQuantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdv Enzyme Regul19842227556382953
   PubMedGoogle Scholar
• ToyoizumiTMickRAbbasAEKangEHKaiserLRMolnar-KimberKLCombined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancerHum Gene Ther199910183013302910609661
   PubMed Web of Science ®Google Scholar
• ChouTCTalalayPGeneralized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitorsEur J Biochem198111512072167227366
   PubMedGoogle Scholar
• ChouTCTheoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studiesPharmacol Rev200658362168116968952
   PubMed Web of Science ®Google Scholar
• NaitoSObayashiSSumiTEnhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamideCancer Gene Ther200613878079116645620
   PubMed Web of Science ®Google Scholar
• EgorinMJSigmanLMVan EchoDAForrestAWhitacreMYAisnerJPhase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusionCancer Res19874726176233791246
   PubMed Web of Science ®Google Scholar
• WoodLWShillitoeEJEffect of a caspase inhibitor, zVADfmk, on the inhibition of breast cancer cells by herpes simplex virus type 1Cancer Gene Ther2011181068569421701533
   PubMed Web of Science ®Google Scholar
• AubertMPomeranzLEBlahoJAHerpes simplex virus blocks apoptosis by precluding mitochondrial cytochrome c release independent of caspase activation in infected human epithelial cellsApoptosis2007121193517080326
   PubMed Web of Science ®Google Scholar
• StanzialeSFPetrowskyHAdusumilliPSBen-PoratLGonenMFongYInfection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activityClin Cancer Res20041093225323215131064
   PubMed Web of Science ®Google Scholar
• EisenbergDPCarpenterSGAdusumilliPSHyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathwaySurgery2010148232533420633729
   PubMed Web of Science ®Google Scholar
• BennettJJAdusumilliPPetrowskyHUp-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207)FASEB J20041891001100315059970
   PubMed Web of Science ®Google Scholar
• KanaiRRabkinSDYipSOncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cellsJ Natl Cancer Inst20121041425522173583
   PubMedGoogle Scholar
• HadjipanayisCGFellows-MayleWDelucaNATherapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced deliveryMol Ther200816111783178818728637
   PubMed Web of Science ®Google Scholar
• EisenbergDPAdusumilliPSHendershottKJ5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancerJ Gastrointest Surg20059810681077 discussion 1077–107916269377
   PubMed Web of Science ®Google Scholar
• RoizmanBThe function of herpes simplex virus genes: a primer for genetic engineering of novel vectorsProc Natl Acad Sci U S A1996932111307113128876131
   PubMed Web of Science ®Google Scholar
• AdusumilliPSChanMKChunYSCisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesotheliomaCancer Biol Ther200651485316294031
   PubMed Web of Science ®Google Scholar
• PetrowskyHRobertsGDKoobyDAFunctional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virusJ Virol200175157050705811435585
   PubMed Web of Science ®Google Scholar
• PasserBJCheemaTZhouBIdentification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replicationCancer Res201070103890389520424118
   PubMed Web of Science ®Google Scholar
• NakanoKTodoTZhaoGEnhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination modelsJ Gene Med20057563864815754306
   PubMed Web of Science ®Google Scholar
• GutermannAMayerEvon Dehn-RothfelserKEfficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cellsHum Gene Ther200617121241125317117895
   PubMed Web of Science ®Google Scholar
• FuXTaoLRiveraAZhangXRapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replicationInt J Cancer201112961503151021128236
   PubMed Web of Science ®Google Scholar
• StanfordMMBarrettJWNazarianSHWerdenSMcFaddenGOncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cellsJ Virol20078131251126017108021
   PubMed Web of Science ®Google Scholar
• AlainTLunXMartineauYVesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN productionProc Natl Acad Sci U S A201010741576158120080710
   PubMed Web of Science ®Google Scholar
• MishraRMiyamotoMYoshiokaTAdenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivoInt J Oncol20093451231124019360336
   PubMed Web of Science ®Google Scholar
• MoormanNJShenkTRapamycin-resistant mTORC1 kinase activity is required for herpesvirus replicationJ Virol201084105260526920181700
   PubMed Web of Science ®Google Scholar
• HalfordWPMaenderJLGebhardtBMRe-evaluating the role of natural killer cells in innate resistance to herpes simplex virus type 1Virol J200525616022737
   PubMed Web of Science ®Google Scholar
• Alvarez-BreckenridgeCAYuJKaurBCaligiuriMAChioccaEADeciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer CellsAdv Virol2012201270283922312364
   PubMedGoogle Scholar
• FulciGBreymannLGianniDCyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProc Natl Acad Sci U S A200610334128731287816908838
   PubMed Web of Science ®Google Scholar
• CurrierMAGillespieRASawtellNMEfficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamideMol Ther200816587988518388918
   PubMed Web of Science ®Google Scholar
• WakimotoHFulciGTyminskiEChioccaEAAltered expression of antiviral cytokine mRNAs associated with cyclophosphamide’s enhancement of viral oncolysisGene Ther200411221422314712306
   PubMed Web of Science ®Google Scholar
• FriedmanATianJPFulciGChioccaEAWangJGlioma virotherapy: effects of innate immune suppression and increased viral replication capacityCancer Res20066642314231916489036
   PubMed Web of Science ®Google Scholar
• FulciGDmitrievaNGianniDDepletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic virusesCancer Res200767199398940617909049
   PubMed Web of Science ®Google Scholar
• PawlikTMNakamuraHMullenJTProdrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgeneCancer20029551171118112209705
   PubMed Web of Science ®Google Scholar
• TyminskiELeroySTeradaKBrain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecanCancer Res200565156850685716061668
   PubMed Web of Science ®Google Scholar
• Bazan-PeregrinoMArvanitisCDRifaiBSeymourLWCoussiosCCUltrasound-induced cavitation enhances the delivery and therapeutic efficacy of an oncolytic virus in an in vitro modelJ Control Release2012157223524221982902
   PubMed Web of Science ®Google Scholar
• TeradaKWakimotoHTyminskiEChioccaEASaekiYDevelopment of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor modelsGene Ther200613870571416421599
   PubMed Web of Science ®Google Scholar
• MillerCGFraserNWRequirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma modelMol Ther20037674174712788647
   PubMed Web of Science ®Google Scholar
• BenenciaFCourregesMCConejo-GarciaJROncolytic HSV exerts direct antiangiogenic activity in ovarian carcinomaHum Gene Ther200516676577815960607
   PubMed Web of Science ®Google Scholar
• EsakiSGoshimaFKimuraHMurakamiSNishiyamaYEnhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor modelsInt J Cancer201313271592160122949155
   PubMed Web of Science ®Google Scholar
• SimpsonGRHorvathAAnnelsNECombination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancerBr J Cancer2012106349650722240799
   PubMed Web of Science ®Google Scholar
• WatanabeDGoshimaFMoriITamadaYMatsumotoYNishiyamaYOncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10J Dermatol Sci200850318519618226503
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• HodiFSObleDADrappatzJCTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNSNat Clin Pract Oncol20085955756118665147
   PubMedGoogle Scholar
• FriedmanGKHaasMCKellyVMMarkertJMGillespieGYCassadyKAHypoxia Moderates gamma(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary CulturesTransl Oncol20125320020722741039
   PubMed Web of Science ®Google Scholar
• AghiMKLiuTCRabkinSMartuzaRLHypoxia enhances the replication of oncolytic herpes simplex virusMol Ther2009171515618957963
   PubMed Web of Science ®Google Scholar
• AmgenIpilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Available from: http://clinicaltrials.gov/show/NCT01740297. NLM identifier: NCT01740297Accessed September 26, 2013
   Google Scholar
• FasulloMBurchADBrittonAHypoxia enhances the replication of oncolytic herpes simplex virus in p53-breast cancer cellsCell Cycle20098142194219719502787
   PubMed Web of Science ®Google Scholar
• SgubinDWakimotoHKanaiRRabkinSDMartuzaRLOncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cellsStem Cells Transl Med20121432233223197811
   PubMed Web of Science ®Google Scholar
• EshunFKCurrierMAGillespieRAFitzpatrickJLBairdWHCripeTPVEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapyGene Ther201017792292920508601
   PubMed Web of Science ®Google Scholar
• DeguchiTShikanoTKasuyaHCombination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancersHepatogastroenterology2012591181844185022172413
   PubMedGoogle Scholar
• CurrierMAEshunFKShollAVEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid CellsMol Ther20132151014102323481323
   PubMed Web of Science ®Google Scholar
• AlbertssonPLennernasBNorrbyKDose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-AActa Oncol200847229330018210302
   PubMed Web of Science ®Google Scholar
• PasserBJCheemaTWuSWuCLRabkinSDMartuzaRLCombination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer modelsCancer Gene Ther2013201172423138870
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NComprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature200845572161061106818772890
   PubMed Web of Science ®Google Scholar
• EngelmanJATargeting PI3K signalling in cancer: opportunities, challenges and limitationsNat Rev Cancer20099855056219629070
   PubMed Web of Science ®Google Scholar
• KudchodkarSBYuYMaguireTGAlwineJCHuman cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinaseJ Virol20047820110301103915452223
   PubMed Web of Science ®Google Scholar
• BuchkovichNJYuYZampieriCAAlwineJCThe TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathwayNat Rev Microbiol20086426627518311165
   PubMed Web of Science ®Google Scholar
• BreitbachCJReidTBurkeJBellJCKirnDHNavigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approvalCytokine Growth Factor Rev2010212–3858920472490
   PubMed Web of Science ®Google Scholar
• LiuTCWakimotoHMartuzaRLRabkinSDHerpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeuticsClin Cancer Res200713195897590217908985
   PubMed Web of Science ®Google Scholar
• KanaiRWakimotoHMartuzaRLRabkinSDA novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cellsClin Cancer Res201117113686369621505062
   PubMed Web of Science ®Google Scholar
• LiuTCCastelo-BrancoPRabkinSDMartuzaRLTrichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effectsMol Ther20081661041104718388912
   PubMed Web of Science ®Google Scholar
• LinSFGaoSPPriceDLSynergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancerClin Cancer Res20081451519152818316577
   PubMed Web of Science ®Google Scholar
• ShimoyamaSGoshimaFTeshigaharaOEnhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination modelsHepatogastroenterology200754761038104217629034
   PubMedGoogle Scholar
• PasserBJCastelo-BrancoPBuhrmanJSVargheseSRabkinSDMartuzaRLOncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cellsCancer Gene Ther200916755156019197321
   PubMed Web of Science ®Google Scholar
• CinatlJJrCinatlJMichaelisMPotent oncolytic activity of multi-mutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcomaCancer Res20036371508151412670897
   PubMed Web of Science ®Google Scholar
• CheemaTAKanaiRKimGWEnhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenograftsClin Cancer Res201117237383739321976549
   PubMed Web of Science ®Google Scholar
• HeoJBreitbachCJMoonASequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyMol Ther20111961170117921427706
   PubMed Web of Science ®Google Scholar
• CabreraRLimayeARHornePThe anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinomaAliment Pharmacol Ther2013371919723094860
   PubMed Web of Science ®Google Scholar
• MahllerYYVaikunthSSCurrierMAOncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft modelMol Ther200715227928617235305
   PubMed Web of Science ®Google Scholar
• DiasJDHemminkiODiaconuITargeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4Gene Ther2012191098899822071969
   PubMed Web of Science ®Google Scholar
• KuluYKawasakiHDonahueJMConcurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysisCancer Gene Ther201320213314023348635
   PubMed Web of Science ®Google Scholar
• LiuBLRobinsonMHanZQICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour propertiesGene Ther200310429230312595888
   PubMed Web of Science ®Google Scholar
• HarringtonKJHingoraniMTanayMAPhase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neckClin Cancer Res201016154005401520670951
   PubMed Web of Science ®Google Scholar
• KemenyNBrownKCoveyAPhase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liverHum Gene Ther200617121214122417107303
   PubMed Web of Science ®Google Scholar
• KellyKJWongJFongYHerpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancyExpert Opin Investig Drugs200817711051113
   PubMed Web of Science ®Google Scholar
• GeevargheseSKGellerDAde HaanHAPhase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liverHum Gene Ther20102191119112820486770
   PubMed Web of Science ®Google Scholar
• SzeDYIagaruAHGambhirSSDe HaanHAReidTRResponse to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomographyHum Gene Ther2012231919721895536
   PubMed Web of Science ®Google Scholar
• YazakiTManzHJRabkinSDMartuzaRLTreatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1Cancer Res19955521475247567585498
   PubMed Web of Science ®Google Scholar
• MinetaTRabkinSDYazakiTHunterWDMartuzaRLAttenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomasNat Med1995199389437585221
   PubMed Web of Science ®Google Scholar
• HunterWDMartuzaRLFeigenbaumFAttenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primatesJ Virol19997386319632610400723
   PubMed Web of Science ®Google Scholar
• TodoTRabkinSDMartuzaRLEvaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumorsCancer Gene Ther20007693994610880026
   PubMed Web of Science ®Google Scholar
• MarkertJMMedlockMDRabkinSDConditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trialGene Ther200071086787410845725
   PubMed Web of Science ®Google Scholar
• MarkertJMLiechtyPGWangWPhase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBMMol Ther200917119920718957964
   PubMed Web of Science ®Google Scholar
• AghiMKChioccaEAPhase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replicationMol Ther20091718919116635
   PubMed Web of Science ®Google Scholar
• HarrowSPapanastassiouVHarlandJHSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survivalGene Ther200411221648165815334111
   PubMed Web of Science ®Google Scholar
• PapanastassiouVRamplingRFraserMThe potential for efficacy of the modified (ICP 34.5(−)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle studyGene Ther20029639840611960316
   PubMed Web of Science ®Google Scholar
• RamplingRCruickshankGPapanastassiouVToxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant gliomaGene Ther200071085986610845724
   PubMed Web of Science ®Google Scholar
• McKieEAMacLeanARLewisADSelective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours – evaluation of a potentially effective clinical therapyBr J Cancer19967457457528795577
   PubMed Web of Science ®Google Scholar
• MaceATHarrowSJGanlyIBrownSMCytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinomaActa Otolaryngol2007127888088717763002
   PubMed Web of Science ®Google Scholar
• NakaoAKasuyaHSahinTTA phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancerCancer Gene Ther201118316717521102422
   PubMed Web of Science ®Google Scholar
• NakaoATakedaSShimoyamaSClinical experiment of mutant herpes simplex virus HF10 therapy for cancerCurr Cancer Drug Targets20077216917417346108
   PubMed Web of Science ®Google Scholar
• KimataHImaiTKikumoriTPilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancerAnn Surg Oncol20061381078108416865590
   PubMed Web of Science ®Google Scholar
• NakaoAKimataHImaiTIntratumoral injection of herpes simplex virus HF10 in recurrent breast cancerAnn Oncol200415698898915151960
   PubMed Web of Science ®Google Scholar
• KohnoSILuoCNawaAOncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virusCancer Gene Ther2007141191892617693992
   PubMed Web of Science ®Google Scholar
• KohnoSLuoCGoshimaFNishiyamaYSataTOnoYHerpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancerUrology20056651116112116286150
   PubMed Web of Science ®Google Scholar
• FujimotoYMizunoTSugiuraSIntratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinomaActa Otolaryngol2006126101115111716923721
   PubMed Web of Science ®Google Scholar
• SahinTTKasuyaHNomuraNImpact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancerCancer Gene Ther201219422923722193629
   PubMed Web of Science ®Google Scholar
• ChahlaviATodoTMartuzaRLRabkinSDReplication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinomaNeoplasia19991216216910933051
   PubMedGoogle Scholar
• SimpsonGRHanZLiuBWangYCampbellGCoffinRSCombination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor controlCancer Res20066694835484216651439
   PubMed Web of Science ®Google Scholar
• WatanabeIKasuyaHNomuraNEffects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancerCancer Chemother Pharmacol200861587588217726607
   PubMed Web of Science ®Google Scholar
• MulleradMBochnerBHAdusumilliPSHerpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinomaJ Urol2005174274174616006968
   PubMed Web of Science ®Google Scholar
• NaganoSPerentesJYJainRKBoucherYCancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumorsCancer Res200868103795380218483263
   PubMed Web of Science ®Google Scholar
• AghiMRabkinSMartuzaRLEffect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replicationJ Natl Cancer Inst2006981385016391370
   PubMedGoogle Scholar
• Children’s Hospital Medical Center, CincinnatiHSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors Available from: http://clinicaltrials.gov/show/NCT00931931. NLM identifier: NCT00931931Accessed September 27, 2013
   Google Scholar
• Virttu Biologics LimitedIntrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. (1716–1712) Available from: http://clinicaltrials.gov/show/NCT01721018. NLM identifier: NCT01721018Accessed September 27, 2013
   Google Scholar
• KennethKTanabeMDrRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors Available from: http://clinicaltrials.gov/show/NCT01071941. NLM identifier: NCT01071941Accessed September 27, 2013
   Google Scholar
• KatsuraTIwaiSOtaYShimizuHIkutaKYuraYThe effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cellsCancer Gene Ther20091623724518949013
   PubMed Web of Science ®Google Scholar
• OtsukiAPatelAKasaiKHistone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic virusesMol Ther2008161546155518648350
   PubMed Web of Science ®Google Scholar
• IsrayelyanAShannonEJBaghianAKearneyMTKousoulasKGThalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSynCancer Chemother Pharmacol2009641201121019308409
   PubMed Web of Science ®Google Scholar